Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities experienced significant gains in Q4, showcasing a strong year. The portfolio showed slight weakness in Q4 but posted a strong absolute return in 2024. In the fourth quarter, the fund’s Investor Class ARTRX returned -1.67%, Advisor Class APDRX posted a return of -1.65% and Institutional Class APHRX returned -1.62%, compared to a -0.99% return for the MSCI All Country World Index. In addition, please check the fund’s top five holdings to know its best picks in 2024.
In its fourth quarter 2024 investor letter, Artisan Global Opportunities Fund emphasized stocks such as Danaher Corporation (NYSE:DHR). Danaher Corporation (NYSE:DHR) manufactures and distributes a diverse portfolio of products and services for professional, medical, industrial, and commercial applications. The one-month return Danaher Corporation (NYSE:DHR) was -15.19%, and its shares lost 15.19% of their value over the last 52 weeks. On April 2, 2025, Danaher Corporation (NYSE:DHR) stock closed at $205.16 per share with a market capitalization of $146.782 billion.
Artisan Global Opportunities Fund stated the following regarding Danaher Corporation (NYSE:DHR) in its Q4 2024 investor letter:
“Among our top detractors were Advanced Micro Devices (AMD), Novo Nordisk and Danaher Corporation (NYSE:DHR). Danaher has transformed itself from a diversified industrial into a health care-focused company through moves such as acquiring the bioprocessing division of GE—one of the leading providers of equipment for making biologic drugs. Like many of its peers, the company has been dealing with the rapid growth and decline of COVID-19 vaccines and then elevated customer inventories from purchases meant to derisk COVID-related supply chain constraints. Shares had performed well heading into its release of Q3 earnings due to investor expectations around a reacceleration coming out of this inventory downcycle. However, results showed that the company was hesitant to indicate this headwind had passed, and management kept its expectations in check. While it is taking longer than anticipated, we believe the company remains well positioned as we head into 2025.”
A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens.
Danaher Corporation (NYSE:DHR) is in 27th position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 101 hedge fund portfolios held Danaher Corporation (NYSE:DHR) at the end of the fourth quarter which was 98 in the previous quarter. In 2024, Danaher Corporation (NYSE:DHR) reported an annual sale of $23.9 billion with a 1.5% decrease in core revenue. In the fourth quarter the company generated $6.5 billion in sales, showing a 1% core revenue growth. While we acknowledge the potential of Danaher Corporation (NYSE:DHR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
We covered Danaher Corporation (NYSE:DHR) in another article, where we shared the list of best healthcare stocks to buy according to billionaires. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.